Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiphospholipid syndrome.

M J Cuadrado1, C Lopez-Pedrera

  • 1Lupus Research Unit, The Rayne Institute, St. Thomas' Hospital, Lambeth Palace Road, SE1 7EH, London, UK. mjcuadrado@yahoo.com

Clinical and Experimental Medicine
|December 4, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic value of quantitative SPECT/CT in assessing active sacroiliitis in patients with axial spondylarthritis and/or inflammatory low back pain.

Anales del sistema sanitario de Navarra·2021
Same author

Pregnancy success rate and response to heparins and/or aspirin differ in women with antiphospholipid antibodies according to their Global AntiphosPholipid Syndrome Score.

Seminars in arthritis and rheumatism·2020
Same author

Immunoglobulin abnormalities are frequent in patients with lupus nephritis.

BMC rheumatology·2019
Same author

The risk of ischaemic stroke in primary antiphospholipid syndrome patients: a prospective study.

European journal of neurology·2017
Same author

Can we withdraw anticoagulation in patients with antiphospholipid syndrome after seroconvertion?

Autoimmunity reviews·2017
Same author

Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease.

Lupus·2017
Same journal

Clonal dynamic changes during the progression of myelodysplastic neoplasms to secondary acute myeloid leukemia: a paired-sample comparison.

Clinical and experimental medicine·2026
Same journal

Silibinin promotes hepatocyte proliferation through PINK1/Parkin-mediated mitophagy to alleviate acetaminophen-induced liver injury.

Clinical and experimental medicine·2026
Same journal

Serum GRP78 as a potential biomarker for early liver injury and active fibrogenesis in alcohol-associated liver disease.

Clinical and experimental medicine·2026
Same journal

Beyond polarization: a receptor-centered framework for macrophage function and therapy in skin diseases.

Clinical and experimental medicine·2026
Same journal

UBA2: the gatekeeper of the sumoylation pathway and its multifaceted roles in human diseases and therapeutic prospects.

Clinical and experimental medicine·2026
Same journal

Clonal Metamorphosis: Deconstructing MPN Evolution with Single-Cell and Spatial Multi-Omics.

Clinical and experimental medicine·2026
See all related articles

Antiphospholipid syndrome (APS) involves thrombosis and pregnancy loss due to antiphospholipid antibodies (aPL). Current management focuses on anticoagulation, with ongoing trials to refine treatment approaches.

Area of Science:

  • Autoimmune diseases
  • Hematology
  • Immunology

Background:

  • Antiphospholipid syndrome (APS) is characterized by thrombosis and pregnancy loss associated with antiphospholipid antibodies (aPL).
  • APS can manifest with diverse clinical symptoms affecting multiple organs.
  • Antiphospholipid antibodies (aPL) are a heterogeneous group detected via immunoassays and coagulation tests.

Purpose of the Study:

  • To review the clinical manifestations, pathogenic mechanisms, and therapeutic strategies for antiphospholipid syndrome (APS).
  • To discuss the current understanding of the role of antiphospholipid antibodies (aPL) in thrombosis development.
  • To highlight the need for evidence-based management guidelines for APS.

Main Methods:

  • Literature review of antiphospholipid syndrome (APS) and antiphospholipid antibodies (aPL).

Related Experiment Videos

  • Analysis of proposed pathogenic mechanisms for thrombosis in APS.
  • Evaluation of current therapeutic recommendations and ongoing clinical trials.

    • Main Results:

    • Antiphospholipid antibodies (aPL) are linked to various thrombotic and non-thrombotic events.
    • Pathogenic mechanisms involve antibody interference with coagulation, platelet and endothelial cell activation, and T-cell responses.
    • Anticoagulation is the primary treatment; immunosuppression appears ineffective.

    Conclusions:

    • Antiphospholipid syndrome (APS) is a complex autoimmune disorder with significant thrombotic risk.
    • Further research and prospective trials are crucial for optimizing APS management.
    • Refined therapeutic approaches are expected from ongoing clinical trials.